data set

data se

Causes of systemic inflammation.

<p>Causes of systemic inflammation.</p

Demographic and clinical profiles of cases and controls.

<p>Demographic and clinical profiles of cases and controls.</p

Multivariate models of effect of baseline CRP on change in UPDRS-III score for the final follow-up period (Days 631–900), as estimated by a generalized linear model.

<p>Multivariate models of effect of baseline CRP on change in UPDRS-III score for the final follow-up period (Days 631–900), as estimated by a generalized linear model.</p

Changes in Unified Parkinson’s Disease Rating Scale Part III (UPDRS-III) scores (A) and L-dopa equivalent dose (LED) (B) by tertile of baseline C-reactive protein (CRP) concentrations.

<p>UPDRS-III score and LED (mg/day) were measured at the study enrollment and during the follow-up period. Subjects were sorted by baseline CRP concentration [≤0.2 mg/L (blue), 0.3–0.6 mg/L (green), and ≥0.7 mg/L (red)]. Symbols, and upper and lower error bars represent mean and 95% CI, respectively.</p

PDVFS.

<p>PDVFS.</p

Flow diagram of participants included in the study.

<p>Flow diagram of participants included in the study.</p

Relevant clinical and other variables of study participants.

<p>Relevant clinical and other variables of study participants.</p

Survival curves of PD patients according to baseline clinical features.

<p>Cumulative survival rates according to CRP levels (A), PD disease duration (B), modified H-Y stages (C), MMSE score (D), age (E), sex (F), NSAID use (G), and serum albumin (H). There was a statistically significant difference in the survival rate between patients with CRP > 0.8 mg/L and ≤ 0.8 mg/L (<i>p</i> = 0.00004) (A), patients with PD disease duration ≤ 8 years and > 8 years (<i>p</i> = 0.00004) (B), those with modified H-Y 1–3 and modified H-Y 4–5 (<i>p</i> = 0.00001) (C), and those with albumin > 4.0mg/dL and albumin ≤ 4.0mg/dL (<i>p</i> = 0.004). However, the survival rate was not influenced by MMSE score, (<i>p</i> = 0.499) (D), age (<i>p</i> = 0.117) (E), sex (<i>p</i> = 0.186) (F), or NSAID use (<i>p</i> = 0.846). Statistical significance was tested using the Log-rank test.</p

Survival curves of PD patients according to CRP levels.

<p>The cumulative survival rate was compared in patients with CRP ≤ 0.8 mg/L and those with CRP > 0.8 mg/L and was stratified by age (A), sex (B), PD duration (C), modified H-Y stage (D), MMSE (E), and serum albumin (F). The cumulative survival rate was significantly higher in patients with CRP ≤ 0.8 mg/L than those with CRP > 0.8 mg/L. Statistical significance was calculated in pooled models.</p